Cortex is a neuroscience company engaged in novel drug therapies for treating psychiatric disorders, neurological diseases and sleep apnea.
The company has posted loss from operations of $986,000, compared to $1.47m for the comparable period in 2009.
For the full year ended 31 December 2010, the company has posted a net income of $1.63m, or $0.02 per diluted share, compared to net loss of $8.44m, or $0.19 per diluted share, for the year ago period.
Cortex has reported its income from operations of $2.18m, compared to loss from operations of $8.34m for the year ago period.